23Andme Holding Co (ME) is a leading diagnostics & research business based in the US. It opened the day at USD$2.23 after a previous close of USD$2.23. During the day the price has varied from a low of USD$2.22 to a high of USD$2.275. The latest price was USD$2.25 (25 minute delay). 23andMe is listed on the NASDAQ and employs 0 staff. All prices are listed in US Dollars.
Promoted for
Global stock trading
Promoted for
Low costs
Promoted for
US stock trading
Promoted for
Asian stocks
| Open | $2.23 |
|---|---|
| High | $2.28 |
| Low | $2.22 |
| Close | $2.25 |
| Previous close | $2.23 |
| Change | $0.02 |
| Change % | 0.8969% |
| Volume | 1,027,500 |
| 52-week range | $2.02 - $6.31 |
|---|---|
| 50-day moving average | $2.47 |
| 200-day moving average | $2.85 |
| Wall St. target price | $5.69 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.73 |
Historical closes compared with the close of $2.25 from 2023-03-24
| 1 week (2023-03-21) | -1.32% |
|---|---|
| 1 month (2023-02-28) | -10.36% |
| 3 months (2022-12-28) | 8.70% |
| 6 months (2022-09-28) | -30.12% |
| 1 year (2022-03-28) | -40.00% |
|---|---|
| 2 years (2021-03-26) | -78.16% |
| 3 years (2020-03-24) | N/A |
| 5 years (2018-03-24) | N/A |
| Revenue TTM | $307.7 million |
|---|---|
| Gross profit TTM | $132.9 million |
| Return on assets TTM | -17.44% |
| Return on equity TTM | -37.04% |
| Profit margin | -103.07% |
| Book value | $1.64 |
| Market capitalisation | $1 billion |
TTM: trailing 12 months
We're not expecting 23andMe to pay a dividend over the next 12 months.
Over the last 12 months, 23andMe's shares have ranged in value from as little as $2.02 up to $6.31. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 23andMe's is 1.4179. This would suggest that 23andMe's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited to leverage genetic insights to validate, develop, and commercialize drugs.
Steps to owning and managing Credit Suisse Group, with 24-hour and historical pricing before you buy.
Social media is the number 1 source of investing advice among young adults in New Zealand, according to new research from Finder.
Everything we know about the upcoming Porsche IPO, plus information on how to buy in.
Find out how Kiwis are investing their money, why they choose to invest and why many are still reluctant with our share trading statistics.
Steps to owning and managing AMTD Digital Inc., with 24-hour and historical pricing before you buy.
An overview of the best investing apps available in NZ, including pros, cons and fees.
What’s the best way to invest money in New Zealand? Find out about KiwiSaver, index funds, cryptocurrency and more in this guide.
Your detailed review of share trading with BlackBull Markets, including brokerage fees, safety, pros and cons, and more.
Thinking of trading shares with Jarden Direct? Check out our review of Jarden Direct fees, safety, and pros and cons first.